C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter H—Medical DevicesPart 812—Investigational Device ExemptionsSubpart A—General Provisions

21 C.F.R. § 812.2 (2026)

Applicability

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 1994–2010 6citing cases
At a glance

Courts have cited this section in 6 opinions since 1994.

(a) General. This part applies to all clinical investigations of devices to determine safety and effectiveness, except as provided in paragraph (c) of this section.

(b) Abbreviated requirements. The following categories of investigations are considered to have approved applications for IDE's, unless FDA has notified a sponsor under § 812.20(a) that approval of an application is required:

(1) An investigation of a device other than a significant risk device, if the device is not a banned device and the sponsor:

(i) Labels the device in accordance with § 812.5;

(ii) Obtains IRB approval of the investigation after presenting the reviewing IRB with a brief explanation of why the device is not a significant risk device, and maintains such approval;

(iii) Ensures that each investigator participating in an investigation of the device obtains from each subject under the investigator's care, informed consent in accordance with part 50 of this chapter.

(iv) Complies with the requirements of § 812.46 with respect to monitoring investigations;

(v) Maintains the records required under § 812.140(b) (4) and (5) and makes the reports required under § 812.150(b) (1) through (3) and (5) through (10);

(vi) Ensures that participating investigators maintain the records required by § 812.140(a)(3)(i) and make the reports required under § 812.150(a) (1), (2), (5), and (7); and

(vii) Complies with the prohibitions in § 812.7 against promotion and other practices.

(2) An investigation of a device other than one subject to paragraph (e) of this section, if the investigation was begun on or before July 16, 1980, and to be completed, and is completed, on or before January 19, 1981.

(c) Exempted investigations. This part, with the exception of § 812.119, does not apply to investigations of the following categories of devices:

(1) A device, other than a transitional device, in commercial distribution immediately before May 28, 1976, when used or investigated in accordance with the indications in labeling in effect at that time.

(2) A device, other than a transitional device, introduced into commercial distribution on or after May 28, 1976, that FDA has determined to be substantially equivalent to a device in commercial distribution immediately before May 28, 1976, and that is used or investigated in accordance with the indications in the labeling FDA reviewed under subpart E of part 807 in determining substantial equivalence.

(3) A diagnostic device, if the sponsor complies with applicable requirements in § 809.10(c) and if the testing:

(i) Is noninvasive,

(ii) Does not require an invasive sampling procedure that presents significant risk,

(iii) Does not by design or intention introduce energy into a subject, and

(iv) Is not used as a diagnostic procedure without confirmation of the diagnosis by another, medically established diagnostic product or procedure.

(4) A device undergoing consumer preference testing, testing of a modification, or testing of a combination of two or more devices in commercial distribution, if the testing is not for the purpose of determining safety or effectiveness and does not put subjects at risk.

(5) A device intended solely for veterinary use.

(6) A device shipped solely for research on or with laboratory animals and labeled in accordance with § 812.5(c).

(7) A custom device as defined in § 812.3(b), unless the device is being used to determine safety or effectiveness for commercial distribution.

(d) Limit on certain exemptions. In the case of class II or class III device described in paragraph (c)(1) or (2) of this section, this part applies beginning on the date stipulated in an FDA regulation or order that calls for the submission of premarket approval applications for an unapproved class III device, or establishes a performance standard for a class II device.

(e) Investigations subject to IND's. A sponsor that, on July 16, 1980, has an effective investigational new drug application (IND) for an investigation of a device shall continue to comply with the requirements of part 312 until 90 days after that date. To continue the investigation after that date, a sponsor shall comply with paragraph (b)(1) of this section, if the device is not a significant risk device, or shall have obtained FDA approval under § 812.30 of an IDE application for the investigation of the device.

[45 FR 3751, Jan. 18, 1980, as amended at 46 FR 8956, Jan. 27, 1981; 46 FR 14340, Feb. 27, 1981; 53 FR 11252, Apr. 6, 1988; 62 FR 4165, Jan. 29, 1997; 62 FR 12096, Mar. 14, 1997; 88 FR 88249, Dec. 21, 2023]
The 6 cases that cite 21 C.F.R. § 812.2 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENUnited States v. Endotec, Inc., 563 F.3d 1187 (11th Cir. 2009).
cites § 812.2 2×cited by 15 cases
Where it cites § 812.2
“In support of their "test[ing] the waters” theory, the Appellees rely upon 21 C.F.R. § 812.2 (c), which lists exemptions from the IDE regulations including the custom device exemption.”
Later courts cite it for
“questions of law subject to de novo review include questions of statutory and regulatory construction.” · 2 citing courts
2
GREENKrumpelbeck v. Breg, Inc., 759 F. Supp. 2d 958 (S.D. Ohio 2010).
cites § 812.2 2×cited by 7 cases
Where it cites § 812.2
“See 21 C.F.R. § 812.2 (c)(2). In the case of Defendant’s alleged “illegal” field trials (Doc.”
Later courts cite it for
“as of the time of plaintiffs surgery, the now-purported association between chondrolysis and anesthetic infusion in the shoulder joint was unknown to defendant, and, indeed, to the entire scientific community,” · 1 citing court
3
GREENSummit Tech., Inc. v. High-Line Med. Instruments Co., 922 F. Supp. 299 (C.D. Cal. 1996).
cites § 812.2 1×cited by 46 cases
Where it cites § 812.2
“§ 360j(b) and 21 C.F.R. §§ 812.2 & 812.3. Clearly, it is within the FDA's domain to determine whether York’s system is a "custom” device.”
The case’s holding
A Lanham Act claim fails if it seeks to redress alleged violations of the Food, Drug, and Cosmetic Act through a private right of action.
Later courts cite it for
“however, a court need not accept as true unreasonable inferences, unwarranted deductions of fact, or conclusory legal allegations cast in the form of factual allegations.” · 9 citing courts
4
GREENGuckin v. Nagle, 259 F. Supp. 2d 406 (E.D. Pa. 2003).
cites § 812.2 1×cited by 8 cases
Where it cites § 812.2
“A detailed regulatory scheme specifies how clinical investigations involving new devices are to be monitored, see 21 C.F.R. § 812.2 (summarizing the lengthy IDE requirements set forth in the body of the regulation).”
5
GREENIn re Cryomedical Sciences, Inc. Sec. Litig., 884 F. Supp. 1001 (D. Md. 1995).
cites § 812.2 1×cited by 13 cases
Where it cites § 812.2
“21 C.F.R. § 812.2 (b). The FDA’s regulations specifically state that, if an abbreviated IDE is available for a device, the device can be shipped to physi *1006 eians prior to a clearance or approval by the FDA.”
6
REDBd. of Med. Examiners v. Duhon, 867 P.2d 20 (Colo. Ct. App. 1994).
cites § 812.2 1×cited by 10 cases
Flagged on editorial review. Superseded by statute: Colo. Rev. Stat. § 12-36-118(4)(a). Only citing opinion saying so: McNiel v. Cooper (Tenn. Ct. App. 2007), filed twice. Verify: syfert.com/caselaw/opinion/1052564/
Summary
No passage or summary on file for this case yet.

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
199420022010

One bar per year. Tallest: 1 case in 1994. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
11th Cir.1C.D. Cal.1Colo. Ct. App.1D. Md.1S.D. Ohio1E.D. Pa.1
By subsection

Courts have not cited this section by subsection, so its cases are not split up here. The Leading cases tab lists the cases that cite it most heavily.

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com